Komen Scholar Dr. Donald McDonnell explains how his work on hormone therapy resistance led to the discovery of elacestrant in his lab. Elacestrant, or Orserdu, was FDA approved in 2023 to treat metastatic estrogen receptor-positive breast cancer with mutations in the ESR1 gene.
Kelsey Hampton, PhD, is Senior Manager, Mission Communications at Susan G. Komen
Dr. Donald McDonnell is a research scientist at Duke University
Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: www.komen.org/...
Link to Survey: susangkomen.ia...
Clinical Trial Finder: www.breastcanc...
Videos:
Breast Cancer Breakthroughs Episode 7: Brining Treatments to Life: • Breast Cancer Breakthr...
Under the Microscope: Mutations: • Mutations and Breast C...
Under the Microscope: Estrogen Receptor: • Estrogen Receptor: Unl...
Resources:
Hormone Receptor Status: www.komen.org/...
Hormone therapy for metastatic breast cancer: www.komen.org/...
EMERALD Trial (Active, not recruiting): www.clinicaltr...
Негізгі бет Breast Cancer Breakthroughs: Dr. Donald McDonnell explains how elacestrant was discovered in his lab
No video
Пікірлер